<DOC>
	<DOCNO>NCT01029132</DOCNO>
	<brief_summary>To investigate characteristic treatment responder galantamine .</brief_summary>
	<brief_title>Characteristics Treatment Responders Galantamine</brief_title>
	<detailed_description>The purpose study : 1. investigate characteristic treatment responder galantamine examine clinical response galantamine patient mild moderate AD 52 week . 2. examine specific cognitive sub-domains sensitive galantamine administration .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>1 . A diagnosis probable AD accord criterion NINCDSADRDA 2 . Korean version MiniMental State Examination score 10 26 3 . History cognitive decline gradual onset progressive least 6 month 4 . A caregiver could assist patient medication , attend assessment provide information patient . 1. evidence neurodegenerative disease AD ( i.e . Parkinson 's disease , Huntington 's disease ) 2 . Psychiatric disorder severe behavioral disturbance require psychotropic medication 3 . Cerebral injury induce trauma , hypoxia , and/or ischemia 4 . Clinically active cerebrovascular disease ; History seizure disorder 5 . Other physical condition require acute treatment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Galantamine</keyword>
	<keyword>Treatment response</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Adverse Event</keyword>
</DOC>